Whats new

Whats new.

Maxim - Is Efti the Answer for Merck's Keytruda Franchise? Going to P3 in 1L Lung is a Big Deal; Maintain Buy, Raise PT to $12 (Analyst: Jason McCarthy, Ph.D.)

June 12th 2024

For a copy of this analyst report please contact your Maxim advisor

Go back